Prognostic factors in follicular lymphoma
Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. It is
usually diagnosed at an advanced stage, for which many treatment options exist, however …
usually diagnosed at an advanced stage, for which many treatment options exist, however …
High-throughput sequencing for noninvasive disease detection in hematologic malignancies
Noninvasive monitoring of minimal residual disease (MRD) has led to significant advances
in personalized management of patients with hematologic malignancies. Improved …
in personalized management of patients with hematologic malignancies. Improved …
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional …
L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao… - Blood, The Journal …, 2013 - ashpublications.org
By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation
(MYD88 L265P) that stimulates nuclear factor κB activity and is present in> 90% of …
(MYD88 L265P) that stimulates nuclear factor κB activity and is present in> 90% of …
Real-time PCR: revolutionizing detection and expression analysis of genes
Invention of polymerase chain reaction (PCR) technology by Kary Mullis in 1984 gave birth
to real-time PCR. Real-time PCR-detection and expression analysis of gene (s) in real-time …
to real-time PCR. Real-time PCR-detection and expression analysis of gene (s) in real-time …
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
MH Delfau-Larue, A van Der Gucht, J Dupuis… - Blood …, 2018 - ashpublications.org
Outcomes for follicular lymphoma (FL) have greatly improved, but most patients will
ultimately relapse. High total metabolic tumor volume (TMTV), computed from baseline 18F …
ultimately relapse. High total metabolic tumor volume (TMTV), computed from baseline 18F …
Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses
Summary Interim 2‐[18F] Fluoro‐2‐deoxy‐D‐glucose Positron Emission Tomography
performed after two chemotherapy cycles (PET‐2) is the most reliable predictor of treatment …
performed after two chemotherapy cycles (PET‐2) is the most reliable predictor of treatment …
[HTML][HTML] Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F Morschhauser, P Marlton, U Vitolo, O Lindén… - Annals of oncology, 2010 - Elsevier
Background Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-
dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its …
dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its …
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial
S Galimberti, S Luminari, E Ciabatti, S Grassi… - Clinical Cancer …, 2014 - AACR
Purpose: The role of the minimal residual disease (MRD) in follicular lymphoma is still
debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a …
debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a …
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell …
C Pott, C Schrader, S Gesk, L Harder, M Tiemann… - Blood, 2006 - ashpublications.org
To evaluate the prognostic impact of minimal residual disease (MRD), quantitative real-time
polymerase chain reaction (RQ-PCR) of clonal IGH rearrangements was performed in 29 …
polymerase chain reaction (RQ-PCR) of clonal IGH rearrangements was performed in 29 …
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
M Ladetto, C Lobetti-Bodoni, B Mantoan… - Blood, The Journal …, 2013 - ashpublications.org
We assessed the prognostic value of minimal residual disease (MRD) within the ML17638
phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab …
phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab …